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INTRODUCTION
Gliomas account for ~80% of malignant primary brain tumors (PBT) 1 . In the United States ~21,000 individuals are diagnosed with glioma annually and for most the prognosis is dismal 1 . To date few lifestyle exposures have consistently been linked to glioma risk except ionizing radiation 1 , which accounts for only a few cases.
An inverse association between self-reported allergic conditions and glioma has been reported in several cohort and case-control studies 2 .
Such data have been interpreted as reflecting a relationship between heightened immune function, seen in atopy, and protection against tumour development. Alternatively the associations observed may be noncausal, arising as a consequence of methodological biases inherent in the study design 2 . These biases include possible selection bias in controls, recall bias from self-reported allergy assessment, and reverse causation or confounding from unmeasured effects. Furthermore, a high frequency of exposure ascertainment by proxy may lead to bias, especially if proxies systematically underreport allergic diseases.
Genetic information provides an alternative approach to assessing the relationship between susceptibility to atopy and tumour risk avoiding these biases. Twin studies have long shown considerable heritability for asthma and atopy phenotypes and furthermore they are strongly correlated with each other 4 . Recent genome-wide association (GWA) studies have identified polymorphisms influencing eosinophil counts 5 and risk of both eczema 6 and asthma 5, 7, 8 . The substantial evidence supporting these findings, including sizeable power and replication in large samples,
indicates that the associations are highly robust.
To determine whether asthma and allergic condition polymorphisms are inversely related to glioma, we interrogated data from the two GWA studies of glioma that we have recently conducted. Since we have used germline polymorphisms as biomarkers of susceptibility to asthma and allergic conditions, our results mitigate against recall bias or effects of glioma on the immune system.
MATERIALS AND METHODS
We extracted data from two GWA studies of glioma 9 . The first was a UK GWA study of 636 cases ascertained through the INTERPHONE Study 10 with individuals from the 1958 Birth Cohort serving as controls 11 . The second was a US GWA study of 1,247 cases ascertained through M.D.
Anderson Cancer Center, Texas with individuals from CGEMS serving as controls 12, 13 . Collection of blood samples and clinical information from subjects was undertaken with informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
As previously described 9 , a genome-wide scan of tagging SNPs was conducted using Illumina Hap550K and Human610-Quad BeadChips according to the manufacturer's protocols (Illumina, San Diego, USA). We subjected cases and controls to rigorous quality control in terms of excluding samples with cryptic relatedness and non-CEU ancestry 9 .
To identify polymorphisms robustly associated with atopic risk we searched PubMed for published articles (January 2000-August 2009) using "atopy, allergy, asthma, eczema, hayfever" in conjunction with "genomewide association" as reference terms. To guard against analyzing variants that may be type 1 errors we took forward only (1) variants that had been replicated in more than one series or had been validated in multi-phase studies involving independent case-control series and (2) that had shown evidence for an association at P < 5.0 x 10 -7 in combined analyses, the significance level advocated for GWA studies. From the literature we identified four loci robustly associated with risk of developing atopy under these criterion. Specifically, rs7216389 mapping to 17q21 (ORMDL3) 8, [14] [15] [16] [17] and rs1588265 mapping to 5q12.1 (PDE4D) 7 , associated with childhood asthma; rs7927894 mapping to 11q13 (C11orf30) associated with atopic dermatitis 6, 18 and rs1420101 mapping to 2q12 (IL1RL1) associated with eosinophil count and risk of asthma 5, 19 .
All SNPs, except for rs7927894, had been genotyped in both GWA studies of glioma. To examine the association between variation at this locus and glioma risk we made use of rs7130588 which is in strong linkage disequilibrium with rs7927894 (r 2 =0.97).
The risk of glioma associated with SNPs was estimated by odds ratios (ORs) using unconditional logistic regression and associated 95%
confidence intervals (CIs) were calculated. All analyses were undertaken using R software and STATA (Version 8.2, Stata Corporation, College
Station, TX, USA). A P-value of < 0.05 was considered statistically significant in all analyses. While our study design precludes adjustment for age effects or putative behavioral and environmental risk factors, these adjustments are unlikely to materially change our conclusions as SNPs are unlikely to have profound age specific effects or strong interactions.
RESULTS AND DISCUSSION
No significant association with glioma risk was seen between rs7130588 or rs1588265 in either case-control series (Table 1 ). An increased risk of glioma was observed between the atopic risk allele of rs1420101 and glioma risk in the US series, but no support was provided by the UK series (combined P = 0.25). A significant association between rs7216389 and glioma risk was shown in the combined dataset (combined P = 0.022);
whereby an increased glioma risk was associated with the risk allele for asthma. While rs7216389 was reported to provide the strongest evidence at 17q21 for an association with asthma, other SNPs mapping to the region were also supportive of a relationship. In view of this we interrogated the region more fully, annotating all SNPs showing significant LD with rs7216389 in order to examine whether a stronger association might emerge (Figure 1 
=1 with rs2040704, P=0.30).
A major strength of our study is that it has been based on a large series of patients and our analysis is unlikely to be confounded by population stratification as we have excluded non-Western European ancestral cases from the analyses. Furthermore, we have only evaluated genetic variants that have previously been shown to be robustly associated with risk of allergy which have been identified by GWA studies of atopy and which were annotated by SNPs typed in our GWA studies of glioma. While this strategy avoids type 1 errors, it has precluded analysis of other potential disease-causing variants. It is also acknowledged that our level of statistical support for an association between ORMDL3 variation and glioma risk does not preclude type 1 error on correction for multiple testing and, as with all association studies, our findings require independent replication.
The overall evidence concerning the nature of the relationship between cancer and allergy is complex and often conflicting with respect to specific tumour types 25, 26 . This wealth of evidence suggests a complex relationship between cancer and allergy, and highlights the requirement for studies in this area to be clearly defined and free from potential bias. In this study we aim to eliminate bias by using genetic information only. This approach has the advantage that these germ line polymorphisms cannot be influenced by the presence of the cancer, unlike self-reporting of allergy or measurement of IgE levels.
This study serves to illustrate the value of using genetics as a tool to develop aetiological hypotheses for cancer risk thus avoiding potential bias in case-control analyses and providing robust evidence in order to determine the true relationship between allergy and glioma.
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